NO321504B1 - Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. - Google Patents
Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. Download PDFInfo
- Publication number
- NO321504B1 NO321504B1 NO19975832A NO975832A NO321504B1 NO 321504 B1 NO321504 B1 NO 321504B1 NO 19975832 A NO19975832 A NO 19975832A NO 975832 A NO975832 A NO 975832A NO 321504 B1 NO321504 B1 NO 321504B1
- Authority
- NO
- Norway
- Prior art keywords
- protein hydrolyzate
- casein
- composition
- preparation
- lactobacillus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 239000003531 protein hydrolysate Substances 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 17
- 238000000338 in vitro Methods 0.000 title claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 48
- 229940039696 lactobacillus Drugs 0.000 claims description 42
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 206010020751 Hypersensitivity Diseases 0.000 claims description 14
- 102000057297 Pepsin A Human genes 0.000 claims description 14
- 108090000284 Pepsin A Proteins 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 14
- 108090000631 Trypsin Proteins 0.000 claims description 14
- 229940111202 pepsin Drugs 0.000 claims description 14
- 239000012588 trypsin Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims description 11
- 201000010859 Milk allergy Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 230000004888 barrier function Effects 0.000 claims description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 230000010585 negative regulation of hypersensitivity Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 230000003614 tolerogenic effect Effects 0.000 claims description 4
- 239000005018 casein Substances 0.000 description 55
- 235000013350 formula milk Nutrition 0.000 description 31
- 102000011632 Caseins Human genes 0.000 description 26
- 108010076119 Caseins Proteins 0.000 description 26
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 26
- 235000021240 caseins Nutrition 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 18
- 206010012438 Dermatitis atopic Diseases 0.000 description 15
- 201000008937 atopic dermatitis Diseases 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 235000020247 cow milk Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 206010003645 Atopy Diseases 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 239000005862 Whey Substances 0.000 description 7
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 108010046377 Whey Proteins Proteins 0.000 description 7
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 7
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 7
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000020614 extensively hydrolysed formula Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000017307 interleukin-4 production Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000020883 elimination diet Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI952926A FI104465B (fi) | 1995-06-14 | 1995-06-14 | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
PCT/FI1996/000350 WO1997000078A1 (en) | 1995-06-14 | 1996-06-12 | Methods of preventing or treating allergies |
Publications (3)
Publication Number | Publication Date |
---|---|
NO975832D0 NO975832D0 (no) | 1997-12-11 |
NO975832L NO975832L (no) | 1997-12-11 |
NO321504B1 true NO321504B1 (no) | 2006-05-15 |
Family
ID=8543602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975832A NO321504B1 (no) | 1995-06-14 | 1997-12-11 | Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. |
Country Status (27)
Country | Link |
---|---|
US (2) | US6506380B1 (de) |
EP (1) | EP0833649B2 (de) |
JP (1) | JP3983804B2 (de) |
KR (1) | KR100494741B1 (de) |
CN (1) | CN1154506C (de) |
AR (1) | AR003960A1 (de) |
AT (1) | ATE230606T1 (de) |
BG (1) | BG63153B1 (de) |
BR (1) | BR9607827A (de) |
CA (1) | CA2224320C (de) |
CZ (1) | CZ291904B6 (de) |
DE (1) | DE69625690T3 (de) |
DK (1) | DK0833649T4 (de) |
EE (1) | EE03424B1 (de) |
ES (1) | ES2191103T5 (de) |
FI (1) | FI104465B (de) |
HK (1) | HK1010081A1 (de) |
IL (1) | IL122577A0 (de) |
MX (1) | MX9710109A (de) |
MY (1) | MY113912A (de) |
NO (1) | NO321504B1 (de) |
NZ (1) | NZ310478A (de) |
PL (1) | PL185123B1 (de) |
RO (1) | RO120243B1 (de) |
SK (1) | SK284245B6 (de) |
WO (1) | WO1997000078A1 (de) |
ZA (1) | ZA965088B (de) |
Families Citing this family (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
ES2317666T3 (es) * | 1997-06-03 | 2009-04-16 | Ganeden Biotech, Inc. | Bacteria acida lactica probiotica para tratar infecciones bacterianas asociadas con el sids. |
WO2000042560A2 (en) | 1999-01-19 | 2000-07-20 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides |
CN1186440C (zh) | 1999-08-05 | 2005-01-26 | 雀巢制品公司 | 预防病原性细菌引起的腹泻的新双歧杆菌 |
DK1353681T3 (da) | 1999-08-05 | 2008-03-10 | Nestle Sa | Bifidobakterier i stand til at modvirke diarré |
US20020031787A1 (en) * | 2000-02-04 | 2002-03-14 | Maclaren Noel K. | Compositions and methods for reducing autoimmunity |
FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
SK3642003A3 (en) | 2000-09-25 | 2003-08-05 | Nestle Sa | Strain of lactic acid bacteria, food and pharmaceutical composition, a vaccine comprising same and its use |
CN100553646C (zh) * | 2000-10-06 | 2009-10-28 | 雀巢产品股份有限公司 | 用乳酸菌微生态制剂调节皮肤免疫系统 |
FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
EP1228707A1 (de) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Verwendung von alpha-lactalbumin als praebiotischer Wirkstoff |
WO2002071874A2 (en) * | 2001-03-09 | 2002-09-19 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−18誘導剤 |
EP1364586A1 (de) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotika und Oraltoleranz |
US20050256057A1 (en) | 2002-06-04 | 2005-11-17 | Luppo Edens | Protein hydrolysate rich in tripeptides |
ES2311729T5 (es) | 2002-06-28 | 2013-02-14 | Biosearch S.A. | Cepas probióticas, un procedimiento para la selección de ellas, composiciones de las mismas y su uso |
EP1384483A1 (de) * | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotische Mikroorganismen zur Behandlung von Colon Irritabile durch die Verbesserung der neuromuskulären Darmfunktion |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
EP1638416B1 (de) | 2003-06-23 | 2013-05-01 | Nestec S.A. | Verwendung von nährstofformulierungen für eine optimale darmbarrierefunktion |
KR20120035233A (ko) | 2004-02-25 | 2012-04-13 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 바실루스 투링기엔시스 결정 폴리펩티드, 폴리뉴클레오티드, 및 이의 조성물 |
US20050265946A1 (en) * | 2004-05-28 | 2005-12-01 | Kao Corporation | Elastase inhibitor |
US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
AU2006233918B2 (en) | 2005-04-13 | 2012-06-21 | Nestec S.A. | Infant formula with probiotics |
US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
JP2009515929A (ja) * | 2005-11-14 | 2009-04-16 | ネステク ソシエテ アノニム | 糖化タンパク質を用いた経口免疫寛容促進 |
MX2008010422A (es) | 2006-02-15 | 2008-10-27 | Nestec Sa | Uso de bifidobacterium longum para la prevencion y tratamiento de inflamacion. |
BRPI0708689A2 (pt) | 2006-03-07 | 2011-06-07 | Nestec Sa | mistura simbiótica |
MY180578A (en) * | 2006-06-15 | 2020-12-02 | Nestec Sa | Induction of tolerance to egg proteins |
WO2008106373A1 (en) * | 2007-02-28 | 2008-09-04 | Mead Johnson Nutrition Company | Product containing inactivated probiotic for children or infants |
CN101273737B (zh) | 2007-03-28 | 2011-08-24 | 哈尔滨正方科技有限公司 | 一种在常温下保持高活菌数的发酵乳饮料的制备方法 |
EP1974743A1 (de) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotika zur Verbesserung der Darm-Biozönose |
EP1974734A1 (de) † | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotika zur Minderung des Risikos von Fettleibigkeit |
EP1974735A1 (de) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Verringerung des Durchfallrisikos |
US7977078B2 (en) | 2007-08-24 | 2011-07-12 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
EP2072052A1 (de) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Verhinderung opportunistischer Infektionen bei Personen mit schwachem Immunsystem |
PL2244593T3 (pl) | 2008-01-24 | 2015-11-30 | Nestec Sa | Kapsułka zawierająca składniki odżywcze i sposób dostarczania cieczy odżywczej z kapsułki |
DK2244734T3 (en) | 2008-02-01 | 2016-08-15 | Murdoch Childrens Res Inst | PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY |
PT2265135T (pt) | 2008-03-14 | 2018-02-21 | Nestec Sa | Mistura simbiótica |
EP2127661A1 (de) | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotika zur Verbesserung der Darm-Biozönose |
US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
CA2726850C (en) | 2008-06-13 | 2015-06-02 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
ES2438576T3 (es) | 2008-06-24 | 2014-01-17 | Codexis, Inc. | Procesos biocatalíticos para la preparación de compuestos de prolina bicíclica fusionada considerablemente pura estereoméricamente |
EP2147678A1 (de) | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotika zur Erhöhung der IgA-Sekretion bei per Kaiserschnitt geborenen Kindern |
HUE026181T2 (en) | 2008-08-27 | 2016-05-30 | Codexis Inc | Ketoreductase polypeptide for the preparation of 3-aryl-3-hydroxypropanamine from 3-aryl-3-ketopropanamine |
EP2385983B1 (de) | 2009-01-08 | 2017-12-20 | Codexis, Inc. | Transaminase-polypeptide |
CA2754580C (en) | 2009-03-17 | 2014-06-17 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
BRPI1010239A2 (pt) | 2009-03-31 | 2016-10-11 | Codexis Inc | endoglucanases aprimoradas, derivados e seus usos |
BRPI1012922A2 (pt) | 2009-06-16 | 2016-10-11 | Codexis Inc | polipeptídeo de b-glicosidase variante, vetor de expressão, célula hospedeira, método de produção de polipeptídeo de b-glicosidase variante, composição enzimática, método de conversão de um substrato de biomassa em açucar fermentável e método de produção de álcool |
DK3409765T3 (da) | 2009-06-22 | 2021-09-27 | Codexis Inc | Ketoreduktase-medieret stereoselektiv rute til alpha-chloralkoholer |
US8614081B2 (en) | 2009-07-23 | 2013-12-24 | Codexis, Inc. | Nitrilase biocatalysts |
RU2539514C2 (ru) * | 2009-08-18 | 2015-01-20 | Нестек С.А. | Питательная композиция, содержащая штаммы bifidobacterium longum и ослабляющая сиптомы пищевой аллергии, особенно у младенцев и детей |
WO2011020780A1 (en) * | 2009-08-18 | 2011-02-24 | Nestec S.A. | A nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children. |
SG178456A1 (en) | 2009-08-19 | 2012-04-27 | Codexis Inc | Ketoreductase polypeptides for the preparation of phenylephrine |
CA2772859C (en) | 2009-09-04 | 2015-05-26 | Codexis, Inc. | Variant cbh2 cellulases and related polynucleotides |
EP2295535A1 (de) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotisches Material |
WO2011035105A1 (en) | 2009-09-18 | 2011-03-24 | Codexis, Inc. | Reduced codon mutagenesis |
CN102666848B (zh) | 2009-11-25 | 2014-09-24 | 科德克希思公司 | 用于从纤维素生物质产生可发酵的糖的重组嗜热子囊菌β-葡糖苷酶变体 |
MX355841B (es) | 2009-11-25 | 2018-05-02 | Codexis Inc | Variantes de beta-glucosidasa recombinante para producción de azúcares solubles de biomasa celulósica. |
SG181535A1 (en) | 2009-12-08 | 2012-07-30 | Codexis Inc | Synthesis of prazole compounds |
RU2563355C2 (ru) | 2009-12-08 | 2015-09-20 | Нестек С.А. | Смесь для грудных детей с пробиотиками и компонентами оболочек жировых шариков молока |
WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
EP2566497B1 (de) | 2010-05-04 | 2015-07-29 | Codexis, Inc. | Biokatalysatoren zur ezetimib-synthese |
EP2569331A1 (de) | 2010-05-10 | 2013-03-20 | Perseid Therapeutics LLC | Polypeptid-inhibitoren von vla4 |
CA2798937A1 (en) | 2010-05-28 | 2011-12-01 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
WO2011159910A2 (en) | 2010-06-17 | 2011-12-22 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol |
US8574878B2 (en) | 2010-06-28 | 2013-11-05 | Behnaz Behrouzian | Fatty alcohol forming acyl reductases (FARs) and methods of use thereof |
AU2011272878B2 (en) | 2010-06-30 | 2015-04-23 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
CA2808098C (en) | 2010-08-16 | 2020-03-10 | Merck Sharp & Dohme Corp. | Process for preparing aminocyclohexyl ether compounds |
CA2807702C (en) | 2010-08-20 | 2018-07-24 | Codexis, Inc. | Use of glycoside hydrolase 61 family proteins in processing of cellulose |
EP2649187B1 (de) | 2010-12-08 | 2017-11-22 | Codexis, Inc. | Biokatalysatoren und verfahren zur synthese von armodafinil |
EE05750B1 (et) | 2011-02-25 | 2015-06-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine |
US8663962B2 (en) | 2011-03-30 | 2014-03-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
WO2012142302A2 (en) | 2011-04-13 | 2012-10-18 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
UA111078C2 (uk) * | 2011-05-03 | 2016-03-25 | Нестек С.А. | Гідролізат білкового субстрату і спосіб його виготовлення |
US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
BR112014004171A2 (pt) | 2011-08-22 | 2018-11-06 | Codexis Inc | variantes da proteína glicósideo hidrolase gh61 e cofatores que aumentam a atividade de gh61 |
CN103998461B (zh) | 2011-09-08 | 2018-02-02 | 科德克希思公司 | 用于合成取代的内酰胺的生物催化剂和方法 |
WO2013048661A1 (en) | 2011-09-30 | 2013-04-04 | Codexis, Inc. | Fungal proteases |
US20130084271A1 (en) * | 2011-10-03 | 2013-04-04 | Kelly Foods Corporation | Probiotic composition for pets and method of providing the same |
US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
BR112014015030A2 (pt) | 2011-12-20 | 2017-06-13 | Codexis Inc | variantes da endoflucanase 1b (eg1b) |
DK2828385T3 (en) | 2012-03-23 | 2018-03-12 | Codexis Inc | BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS |
US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
US9790527B2 (en) | 2012-05-08 | 2017-10-17 | Codexis, Inc. | Engineered proline hydroxylase polypeptides |
WO2013170050A1 (en) | 2012-05-11 | 2013-11-14 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
BR112014031024A2 (pt) | 2012-06-11 | 2017-06-27 | Codexis Inc | xilanases e xilosidases fúngicas. |
CA2891482A1 (en) | 2012-11-20 | 2014-05-30 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
ES2672328T3 (es) | 2012-12-07 | 2018-06-13 | Merck Sharp & Dohme Corp. | Proceso de transaminación biocatalítica |
HUE051359T2 (hu) | 2012-12-21 | 2021-03-01 | Codexis Inc | Génmódosított biokatalizátorok és eljárások királis aminok szintetizálására |
US9540622B2 (en) | 2013-01-18 | 2017-01-10 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
HUE042206T2 (hu) | 2013-02-28 | 2019-06-28 | Codexis Inc | Módosított transzamináz polipeptidek ipari biokatalízishez |
CN103355405A (zh) * | 2013-04-07 | 2013-10-23 | 苏州旭优食品科技有限公司 | 一种低过敏性含乳制品的加工工艺 |
ES2729048T3 (es) | 2013-04-18 | 2019-10-30 | Codexis Inc | Polipéptidos de fenilalanina amoníaco-liasa modificados |
WO2015073555A1 (en) | 2013-11-13 | 2015-05-21 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
HUE056444T2 (hu) | 2014-04-16 | 2022-02-28 | Codexis Inc | Génmódosított tirozin-ammónia-liáz |
US9708587B2 (en) | 2014-07-09 | 2017-07-18 | Codexis, Inc. | P450-BM3 variants with improved activity |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
SG11201703258PA (en) | 2014-11-25 | 2017-05-30 | Codexis Inc | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
HUE062016T2 (hu) | 2014-12-22 | 2023-09-28 | Codexis Inc | Humán alfa-galaktozidáz variánsok |
EP3256577B1 (de) | 2015-02-10 | 2020-08-26 | Codexis, Inc. | Ketoreduktase-polypeptide zur synthese von chiralen verbindungen |
KR102604503B1 (ko) | 2015-05-07 | 2023-11-20 | 코덱시스, 인코포레이티드 | 페니실린-g 아실라아제 |
WO2017007547A1 (en) | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
JP7128519B2 (ja) | 2016-05-05 | 2022-08-31 | コデクシス, インコーポレイテッド | ペニシリンgアシラーゼ |
CN109715817B (zh) | 2016-06-09 | 2022-12-09 | 科德克希思公司 | 用于化合物的羟基化的生物催化剂和方法 |
KR20190018512A (ko) | 2016-06-15 | 2019-02-22 | 코덱시스, 인코포레이티드 | 조작된 베타-글루코시다아제 및 글루코실화 방법 |
IL264686B1 (en) | 2016-08-26 | 2024-03-01 | Codexis Inc | Engineered imine reductases and methods for reversible amination of ketone and amine compounds |
EP3565893A4 (de) | 2017-01-05 | 2020-12-09 | Codexis, Inc. | Penicillin-g-acylasen |
WO2018144679A2 (en) | 2017-02-03 | 2018-08-09 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
EP3579867A4 (de) | 2017-02-13 | 2021-03-10 | Codexis, Inc. | Manipulierte phenylalanin-ammoniak-lyase-polypeptide |
CA3060715A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
CA3061133A1 (en) | 2017-04-27 | 2018-11-01 | Codexis, Inc. | Ketoreductase polypeptides and polynucleotides |
WO2018208665A1 (en) | 2017-05-08 | 2018-11-15 | Codexis, Inc. | Engineered ligase variants |
CA3064574A1 (en) | 2017-06-14 | 2018-12-20 | Codexis, Inc. | Engineered transaminase polypeptides for industrial biocatalysis |
US11643642B2 (en) | 2017-06-27 | 2023-05-09 | Codexis, Inc. | Penicillin-g acylases |
EP3645711A4 (de) | 2017-06-30 | 2021-04-21 | Codexis, Inc. | T7-rna-polymerasevarianten |
CA3066767A1 (en) | 2017-06-30 | 2019-01-03 | Codexis, Inc. | T7 rna polymerase variants |
US11319531B2 (en) | 2017-11-07 | 2022-05-03 | Codexis, Inc. | Transglutaminase variants |
AU2018383752A1 (en) | 2017-12-13 | 2020-05-21 | Codexis, Inc. | Carboxyesterase polypeptides for amide coupling |
JP7401435B2 (ja) | 2017-12-13 | 2023-12-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | カルボキシエステラーゼ生体触媒 |
WO2019241132A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
US11466259B2 (en) | 2018-07-09 | 2022-10-11 | Codexis, Inc. | Engineered galactose oxidase variant enzymes |
SG11202012111UA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered purine nucleoside phosphorylase variant enzymes |
CA3103721A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered deoxyribose-phosphate aldolases |
US11034948B2 (en) | 2018-07-09 | 2021-06-15 | Codexis, Inc. | Engineered phosphopentomutase variant enzymes |
EP3820991A4 (de) | 2018-07-09 | 2022-07-06 | Codexis, Inc. | Manipulierte enzyme mit pantothenatkinasevarianten |
CN112672989A (zh) | 2018-07-12 | 2021-04-16 | 科德克希思公司 | 工程化苯丙氨酸氨裂合酶多肽 |
BR112021001661A8 (pt) | 2018-07-30 | 2022-08-09 | Codexis Inc | Glicosiltransferase modificada, polinucleotídeo modificado, vetor, célula hospedeira, métodos para produzir pelo menos uma glicosiltransferase modificada, para produzir pelo menos uma variante de sacarose sintase, para glicosilação de um substrato, para produzir rebaudiosídeo m, rebaudiosídeo a e/ou rebaudiosídeo i e rebaudiosídeo d, composição, sacarose sintase modificada, pelo menos um rebaudiosídeo, rebaudiosídeo m, rebaudiosídeo a, rebaudiosídeo i, e, rebaudiosídeo d. |
US11060075B2 (en) | 2018-10-29 | 2021-07-13 | Codexis, Inc. | Engineered DNA polymerase variants |
SG11202105668PA (en) | 2018-12-14 | 2021-06-29 | Codexis Inc | Engineered tyrosine ammonia lyase |
CA3123598A1 (en) | 2018-12-20 | 2020-06-25 | Codexis, Inc. | Human alpha-galactosidase variants |
MX2022000903A (es) | 2019-07-23 | 2022-02-14 | Frieslandcampina Nederland Bv | Composicion nutricional que comprende inmunoglobulina y grasa de la leche. |
MX2022002473A (es) | 2019-08-30 | 2022-08-02 | Codexis Inc | Variantes de lipasa modificadas geneticamente. |
JP2022547523A (ja) | 2019-09-12 | 2022-11-14 | コデクシス, インコーポレイテッド | 10-アセチル-3,7-ジヒドロキシフェノキサジンに対するペルオキシダーゼ活性 |
AU2020358714A1 (en) | 2019-10-02 | 2022-05-12 | Abbott Diabetes Care Inc. | Detection of analytes by protein switches |
BR112022011760A2 (pt) | 2019-12-20 | 2022-08-30 | Codexis Inc | Fragmento de alfa glicosidase ácida recombinante e/ou de alfa glicosidase ácida recombinante biologicamente ativa, alfa glicosidase ácida recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, vetor de expressão pdh, célula hospedeira, método para produzir uma variante de alfa glicosidase ácida recombinante, variante de alfa glicosidase ácida recombinante, composição farmacêutica para o tratamento da doença de pompe, composição farmacêutica, método para tratar e/ou prevenir os sintomas da doença de pompe em um indivíduo, e, uso das composições |
EP4133064A2 (de) | 2020-04-10 | 2023-02-15 | Codexis, Inc. | Gentechnisch hergestellte transaminasepolypeptide |
WO2022047262A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
BR112023003643A2 (pt) | 2020-08-28 | 2023-03-28 | Codexis Inc | Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso |
WO2022125960A1 (en) | 2020-12-11 | 2022-06-16 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
WO2022133289A2 (en) | 2020-12-18 | 2022-06-23 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
EP4314261A1 (de) | 2021-04-02 | 2024-02-07 | Codexis, Inc. | Manipulierte enzyme mit acetatkinasevarianten |
IL305922A (en) | 2021-04-02 | 2023-11-01 | Codexis Inc | Transgenic enzymes of variant guanylate kinase |
WO2022212832A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered cyclic gmp-amp synthase (cgas) variant enzymes |
EP4314263A1 (de) | 2021-04-02 | 2024-02-07 | Codexis, Inc. | Manipulierte enzyme der adenylatkinasevariante |
CA3227215A1 (en) | 2021-07-30 | 2023-02-02 | Trish Choudhary | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
EP4388088A1 (de) | 2021-08-19 | 2024-06-26 | Willow Biosciences, Inc. | Rekombinante olivensäurecyclasepolypeptide, die für eine verbesserte biosynthese von cannabinoiden manipuliert sind |
WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886288A (en) * | 1970-06-15 | 1975-05-27 | Swift & Co | Cheese manufacture using highly active proteolytic enzymes |
JPS5279086A (en) | 1975-12-25 | 1977-07-02 | Nippon Soda Co Ltd | Preparation of antibiotic tunicamycin |
JPS5279083A (en) * | 1975-12-26 | 1977-07-02 | Morinaga Milk Industry Co Ltd | Production of protein decomposed substance not having bitterness and antigen property |
JPS6041751B2 (ja) | 1976-06-22 | 1985-09-18 | ジエコ−株式会社 | デジタル電子時計 |
JPS548785A (en) | 1977-06-21 | 1979-01-23 | Kikkoman Corp | Preparation of protein hydrolyzate |
US4839281A (en) † | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
ATE84680T1 (de) † | 1987-12-23 | 1993-02-15 | Nestle Sa | Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels. |
DD281540A5 (de) | 1988-08-08 | 1990-08-15 | Berlin Chemie Veb | Verfahren zur herstellung von nutritiva |
ATE113441T1 (de) † | 1989-10-02 | 1994-11-15 | Sandoz Nutrition Ltd | Proteinhydrolysaten. |
JP3071877B2 (ja) † | 1991-06-27 | 2000-07-31 | 財団法人糧食研究会 | 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物 |
US5952034A (en) * | 1991-10-12 | 1999-09-14 | The Regents Of The University Of California | Increasing the digestibility of food proteins by thioredoxin reduction |
ATE161181T1 (de) * | 1992-07-06 | 1998-01-15 | Nestle Sa | Lactobacillus acidophilus enthaltende antigastritis-mittel |
FI94089C (fi) | 1992-12-10 | 1995-07-25 | Valio Oy | Menetelmä allergiaa aiheuttavien yhdisteiden poistamiseksi proteiinipitoisista koostumuksista |
RU2031586C1 (ru) | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
GB9312369D0 (en) * | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
WO1995014485A1 (fr) | 1993-11-23 | 1995-06-01 | Kabushiki Kaisha Wado Doctors Group | Composition adjuvante de flore intestinale et appareil et systeme de production |
FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
-
1995
- 1995-06-14 FI FI952926A patent/FI104465B/fi not_active IP Right Cessation
-
1996
- 1996-06-11 MY MYPI96002357A patent/MY113912A/en unknown
- 1996-06-12 CN CNB961947527A patent/CN1154506C/zh not_active Expired - Lifetime
- 1996-06-12 AT AT96918707T patent/ATE230606T1/de active
- 1996-06-12 KR KR1019970709383A patent/KR100494741B1/ko not_active IP Right Cessation
- 1996-06-12 PL PL96324010A patent/PL185123B1/pl unknown
- 1996-06-12 NZ NZ310478A patent/NZ310478A/xx not_active IP Right Cessation
- 1996-06-12 DE DE69625690T patent/DE69625690T3/de not_active Expired - Lifetime
- 1996-06-12 DK DK96918707T patent/DK0833649T4/da active
- 1996-06-12 BR BR9607827-8A patent/BR9607827A/pt not_active Application Discontinuation
- 1996-06-12 WO PCT/FI1996/000350 patent/WO1997000078A1/en not_active Application Discontinuation
- 1996-06-12 CZ CZ19973997A patent/CZ291904B6/cs not_active IP Right Cessation
- 1996-06-12 SK SK1715-97A patent/SK284245B6/sk not_active IP Right Cessation
- 1996-06-12 JP JP50267197A patent/JP3983804B2/ja not_active Expired - Lifetime
- 1996-06-12 IL IL12257796A patent/IL122577A0/xx not_active IP Right Cessation
- 1996-06-12 CA CA2224320A patent/CA2224320C/en not_active Expired - Lifetime
- 1996-06-12 US US08/973,963 patent/US6506380B1/en not_active Expired - Lifetime
- 1996-06-12 EP EP96918707A patent/EP0833649B2/de not_active Expired - Lifetime
- 1996-06-12 RO RO97-02328A patent/RO120243B1/ro unknown
- 1996-06-12 ES ES96918707T patent/ES2191103T5/es not_active Expired - Lifetime
- 1996-06-12 EE EE9700339A patent/EE03424B1/xx unknown
- 1996-06-13 AR ARP960103134A patent/AR003960A1/es unknown
- 1996-06-14 ZA ZA965088A patent/ZA965088B/xx unknown
-
1997
- 1997-12-11 NO NO19975832A patent/NO321504B1/no not_active IP Right Cessation
- 1997-12-11 MX MX9710109A patent/MX9710109A/es unknown
- 1997-12-23 BG BG102144A patent/BG63153B1/bg unknown
-
1998
- 1998-09-24 HK HK98110938A patent/HK1010081A1/xx not_active IP Right Cessation
-
2002
- 2002-12-18 US US10/321,661 patent/US7172756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO321504B1 (no) | Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. | |
Majamaa et al. | Probiotics: a novel approach in the management of food allergy | |
Sütas et al. | Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG–derived enzymes | |
Brouwer et al. | No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trial | |
Mine et al. | Recent advances in the understanding of egg allergens: basic, industrial, and clinical perspectives | |
RU2539514C2 (ru) | Питательная композиция, содержащая штаммы bifidobacterium longum и ослабляющая сиптомы пищевой аллергии, особенно у младенцев и детей | |
US9707258B2 (en) | Bioconversion of milk with Bifidobacterium breve for treatment of allergic manifestions in infants | |
Uncuoglu et al. | Tolerance to baked and fermented cow's milk in children with IgE-mediated and non-IgE-mediated cow's milk allergy in patients under two years of age | |
CN117224652A (zh) | 最新鉴定出的用于诱导幼年哺乳动物口服耐受性的肽 | |
Isolauri | Intestinal involvement in atopic disease | |
Prioult et al. | Allergenicity of acidic peptides from bovine β-lactoglobulin is reduced by hydrolysis with Bifidobacterium lactis NCC362 enzymes | |
Xu et al. | Effect of lactic acid bacteria fermentation on cow milk allergenicity and antigenicity: A review | |
RU2174012C2 (ru) | Способы профилактики или лечения аллергии | |
AU710126C (en) | Methods of preventing or treating allergies | |
Rosetta et al. | On the role of breastfeeding in health promotion and the prevention of allergic diseases | |
Businco et al. | Food allergy and atopic dermatitis. | |
Biscola et al. | Lactic Acid Bacteria Application to Decrease Food Allergies | |
Ouwehand et al. | From hypoallergenic foods to anti-allergenic foods | |
Schouten et al. | Nutrition and food allergy | |
Ritz | Probiotics for the Prevention of Childhood Eczema | |
CZ22359U1 (cs) | Hypoalergenní mléčný přípravek pro dospívající a dospělou populaci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |